11:00 am - 11:40 am

40min

Panel discussion: Next wave in medicine: Accelerating and reducing cost of cell & gene therapy production by better defining cell & viral quality.​

Cell & gene therapies are considered the next big wave in medicine. With projected revenues of close to 30 billion EUR in 2026, CGTs are expected to transform the pharmaceutical industry. Yet many CGTs developers continue to rely on platforms designed for large-molecule drug production that pose inadequacies when superimposed on less stable and time critical biological therapy production. During this panel we will explore the special requirements for QC and process analytical technologies in cell & gene therapy manufacturing, provide an overview of already existing solution and discuss areas where innovations are still needed to accelerate production, reduce costs, and thereby make these new therapies accessible to more patients world-wide.
Thilo Kaltenbach
Thilo Kaltenbach
roland berger logo
Volker Gatterdam
300_90_investor_company_dxpx_eu_2022_logo_speaker_lino_biotech_ag

11:00 am - 11:40 am

40min

Fireside chat: From Academics to Entrepreneurs. Let’s talk about the journey and the transitions.

Deeptech innovations typically originate from years long academic or corporate research and require significant funding and often require expensive laboratory access for years of further development. Compared to virtual business concepts the barriers for success are higher and investors with sufficient endurance and understanding for these business’ are not always easy to find. Here we will learn from successful entrepreneurs and accelerators about steps that need to be taken to make a deeptech startup fundable and pruned for success.
Frank Schäfer
Frank Schäfer
sponsor bioecho
300_300_speaker_dxpx_EU_2022_photo_fabian
Fabian Scheugenpflug
300_90_speaker_company_dxpx_eu_2022_logo_plug_n_play
Frauke Hangen
Frauke Hangen
bioriver
Jessica McCreadie
Jessica McCreadie
octopus ventures

3:00 pm - 3:40 pm

40min

Panel discussion

How to develop medical innovations in Europe and overcome regional reimbursement barriers.

300_300_investor_dxpx_us_2022_photo_Jana_Grieb
Jana Grieb
McDermott Will & Emery LLP

11:00 am - 11:40 am​

40min

Panel discussion: Navigating the Accelerator and Startup Ecosystem.

Accelerators play an important role in fostering innovation by providing intensive development programs that help young entrepreneurs about marketing, finance, and other aspects of business management. Accelerators use well-organized programs to quickly impart years of experience in a short amount of time so that early-stage companies will get the speed they need to be. On this panel we will learn from some of the biggest accelerators in Europe about their programs and success stories where the accelerator made a significant impact for their alumni. We will also learn what accelerator programs are available for European startups most importantly, when is the right stage for startups to apply and what prerequisites should they fulfil.
300_300_speaker_dxpx_EU_2022_photo_eit_helter
Christina Hertel
300_90_investor_dxpx_us_2022_logo_eit_logo

3:00 pm - 3:20 pm

20min

Fireside chat: Digital health: The future of E-health.

The global eHealth market is anticipated to develop at a CAGR of 14.5 percent from 2020 to 2027, reaching $230.64, according to Allied Market Research. The market is expanding due to the rise in chronic diseases, the expansion of government programs to encourage eHealth solutions, and the increasing demand for eHealth solutions to manage regulatory compliance. A better medical history can be created by using eHealth and digitizing personal health data. The eHealth sector strives for better electronic records and health data management. There are countless advantages to eHealth treatment, and they all work together to enhance chronic health management. In this fireside chat, we will learn challenges and opportunities in the digital health ecosystem and provide best practices on how to navigate e-health.
Christoph Brandenberger
Christoph Brandenberger
Brown Gibbons Lang & Company LLC